Sangamo Biosciences, Inc. (SGMO) Reports In-Line Q4 EPS Loss of $0.12
Sangamo Biosciences, Inc. (NASDAQ: SGMO) reported Q4 EPS of ($0.12), in-line with the analyst estimate of ($0.12). Revenue for the quarter came in at $4.7 million versus the consensus estimate of $3.41 million.
Sangamo Biosciences, Inc. sees FY2012 revenue of $14-$18 million, versus the consensus of $16.23 million.
For earnings history and earnings-related data on Sangamo Biosciences, Inc. (SGMO) click here.
Sangamo Biosciences, Inc. sees FY2012 revenue of $14-$18 million, versus the consensus of $16.23 million.
For earnings history and earnings-related data on Sangamo Biosciences, Inc. (SGMO) click here.